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ABSTRACT INTRODUCTION
There are several genetically different 
conditions under which higher levels of fetal 
hemoglobin (HbF) synthesis can persist into 
adult life. The clinical importance of the 
persistence of HbF expression in adults in 
relation to certain dyserythropoietic diseases 
remains controversial. However, acquired HbF 
elevation has been implicated as a prognostic 
factor in myelodysplastic syndrome (MDS) 
and aplastic anemia (AA).1,2
There are many factors that could change 
the level of HbF in adults, such as age, sex, 
polymorphisms, β-globin locus control region 
(LCR) and HbF persistence. Among the poly-
morphic genetic markers of the β-globin gene 
cluster, the XmnI polymorphism, a common 
C→T variation at position –158 of the Gγ 
globin gene, and a set of sequence variations 
in the 5’ hypersensitive site (HS2) of the LCR 
have been associated with increased HbF levels 
in normal individuals, and in β-thalassemia 
and sickle cell anemia patients.2,3
OBJECTIVE
Our objectives were to examine acquired 
HbF increases in AA and paroxysmal noc-
turnal hemoglobinuria (PNH) patients, and 
to evaluate whether there is an association 
between the presence of XmnI and 5’ hyper-
sensitive site locus control region (LCR-HS2) 
polymorphisms and the HbF levels.
MATERIAL AND METHODS
Setting. This was a cross-sectional study 
carried out within the Hematology and Blood 
Transfusion Service of Escola Paulista de Me-
dicina, Universidade Federal de São Paulo, 
São Paulo, Brazil.
Study plan. Thirty-seven patients were 
included in this study: 27 AA patients (13 fe-
males and 14 males) with a mean age of 39.44 
years (range from 15 to 73); and 10 PNH 
patients (5 females and 5 males) with a mean 
age of 48.10 years (range from 22 to 81).
Hematological and hemoglobin analysis. 
Hematological indices were determined using 
an automated cell counter. HbF was measured 
by alkali denaturation. The diagnoses of AA 
and PNH were based on clinical and labora-
tory features, including bone marrow biopsy, 
Ham’s test and flow cytometry.
DNA studies. The presence of XmnI 
polymorphism of the Gγ gene was established 
by means of the polymerase chain reaction, 
followed by digestion with XmnI. The nucleo-
tide sequence of the LCR-HS2 region was 
determined by an allele-specific sequencing 
procedure.3
Statistical analysis. All the results were 
investigated by statistical comparison using 
the Fisher test.
Ethics. This study was approved by the 
Ethical Committee of Universidade Federal 
de São Paulo — Escola Paulista de Medicina 
(Unifesp-EPM).
RESULTS
The percentages of patients with el-
evated HbF were 59% in the AA group and 
40% in the PNH group. The mean HbF 
level in our study was 2.32% (standard de-
viation, SD: 2.47). There was no significant 
difference in HbF levels between the AA and 
PNH groups, which were 2.58 and 1.62% 
respectively (p = 0.46).
The time when the disease was diag-
nosed was unrelated to the HbF level. Simi-
larly, no correlation was observed between 
length of time with the disease and XmnI 
polymorphism.
Analysis of DNA from both groups 
showed that there were twelve (44.45%) XmnI 
heterozygotes and three (11.12%) XmnI ho-
mozygotes in the AA group; and one (10.00%) 
heterozygote and one (10.00%) homozygote 
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CONTEXT AND OBJECTIVE: Acquired fetal hemo-
globin (HbF) elevation has been implicated as a 
prognostic factor in dyserythropoietic disorders. 
Our objectives were to examine acquired HbF in-
creases in aplastic anemia (AA) and paroxysmal 
nocturnal hemoglobinuria (PNH) patients, and to 
evaluate whether there is an association between 
the presence of XmnI and 5’ hypersensitive site 
locus control region (LCR-HS2) polymorphisms 
and the HbF levels.
DESIGN AND SETTING: Cross-sectional study at 
the Hematology and Blood Transfusion Service 
of Universidade Federal de São Paulo — Escola 
Paulista de Medicina.
METHODS: We studied a group of 37 patients 
with AA and/or PNH. Polymerase chain 
reaction (PCR) and enzymatic digestion were 
utilized to analyze XmnI polymorphisms; and 
PCR, cloning and automated sequencing for 
the HS2 polymorphisms.
RESULTS: The mean HbF level was 2.32%, but 
there was no significant difference in HbF level 
between the AA and PNH groups (p = 0.46). 
HbF levels of less than 1.0% showed a significant 
correlation with absence of the XmnI (+) polymor-
phism (p = 0.02). The presence of the XmnI allele 
was greater in the AA group (p = 0.007).
CONCLUSIONS: XmnI polymorphism absence 
reduction is associated with acquired HbF eleva-
tion. Further studies are required to confirm these 
observations and make treatment, prognosis and 
survival comparisons.
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in the PNH group. The presence of the XmnI 
allele was significantly higher in the AA group 
(p = 0.007) (Table 1). The HbF level was com-
pared with presence or absence of the XmnI 
allele, and it was found that HbF levels of less 
than 1.0% had a significant correlation with 
absence of the polymorphism (p = 0.02).
The presence of LCR-HS2 polymorphism 
was observed in only one patient with AA. The 
patient was an African-Brazilian man with 
AA, presenting XmnI (-) and HbF of 6.2%. 
The polymorphism observed was the same as 
the Benin haplotype described in sickle cell 
disease, which could be associated with the 
patient’s ethnic group.
DISCUSSION
Elevated expression of HbF substantially 
benefits patients with β-globin disorders.1 
On the other hand, increased HbF levels in 
acquired hemopathy has been associated with 
a better prognosis.1,2
In our study, the HbF level was consider-
ably higher than expected, as was the frequen-
cy of patients with elevated HbF. The presence 
of hereditary persistence of fetal hemoglobin 
Table 1. XmnI allele polymorphism (-158 Gγ allele C/T polymorphism) analysis accor-
ding to aplastic anemia group (AA) and paroxysmal nocturnal hemoglobinuria group 
(PNH); p = 0.007
XmnI (+) XmnI (-)
Disease n (%) n (%) Total
PNH 3 (4%) 17 (23%) 20 (27%)
AA 28 (38%) 26 (35%) 54 (73%)
Total 31 (42%) 43 (58%) 74 (100%)
C = cytosine; T = thymine.
in Brazil has been shown to be approximately 
0.01%, while we observed 59% and 40% in 
the AA and PNH patients, respectively.4 These 
data confirm the association between elevated 
HbF level and hematopoietic stress that was 
described previously.2
Although there is a need for better un-
derstanding of the meaning of the presence of 
HbF in adults, few reports have evaluated the 
importance of XmnI and LCR-HS2 polymor-
phisms in populations without hemoglobin 
disorders.1-3 We showed a XmnI polymorphism 
rate of 45.94% in our sample, with significant 
correlation with the HbF level. These results 
are consistent with previous Brazilian work on 
AA that showed higher Gγ values with higher 
HbF levels in bone marrow failure syndromes.5 
However, no correlation with the length of time 
since the diagnosis was found.
CONCLUSIONS
We conclude that XmnI polymorphism is 
probably implicated in acquired HbF eleva-
tion in hypoplastic syndromes. Further studies 
are required to confirm these observations 
and make treatment, prognosis and survival 
comparisons with regard to these hematologi-
cal disorders.
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RESUMO
Polimorfismo XmnI está associado com os níveis de hemoglobina fetal em hipoplasias medulares
CONTEXTO E OBJETIVO: O aumento adquirido da hemoglobina fetal (HbF) já foi implicado como fator 
prognóstico em distúrbios diseritropoiéticos. Nossos objetivos foram de examinar elevações adquiridas na 
HbF em pacientes com anemia aplástica (AA) e hemoglobinúria paroxística noturna (PNH), e de avaliar 
se há associação entre a presença de polimorfismos XmnI e de região de controle de locus gênico 5´ 
(LCR-HS2) e os níveis de HbF.
TIPO DE ESTUDO E LOCAL: Estudo longitudinal no Serviço de Hematologia e Transfusão de Sangue da 
Universidade Federal de São Paulo – Escola Paulista de Medicina.
MÉTODOS: Estudamos um grupo de 37 pacientes com AA e/ou PNH. Reação de polimerase em cadeia 
(PCR) e digestão enzimática foram usadas para analisar polimorfismos XmnI; e PCR para clonagem e 
sequenciamento automático dos polimorfismos HS2.
RESULTADOS: O nível médio de HbF foi de 2,32%, mas não houve diferença significativa entre o nível 
de HbF dos pacientes AA e PNH (p = 0.46). Os níveis de HbF menores que 1,0% mostraram correlação 
estatisticamente significativa com ausência do polimorfismo XmnI (+) (p = 0.007).
CONCLUSÕES: Ausência de polimorfismo XmnI está associado com diminuição de HbF. Mais estudos 
são necessários para confirmar estas observações e fazer comparações sobre tratamento, prognóstico 
e sobrevida.
PALAVRAS-CHAVE: Polimorfismo (Genética). Anemia aplástica. Hemoglobinúria paroxística. Hemoglobina 
fetal. Reação em cadeia da polimerase.
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